Hao Chen, PhD — The Max Harry Weil Institute for Critical Care Research and Innovation

Research Investigator, Biomedical Engineering

Dr. Hao Chen’s research interests are in the areas of electrochemical and optical sensors in microfluidic systems, nitric oxide releasing/generating biomaterials for urinary and dialysis infections and dysfunction, solutions for critical care, stem cell biocompatible systems, micro and macro bio implantable solutions, and technology translation. Hao has contributed in the development of biomedical materials, Raman based SERS technology, nephrostomy balloons, spinal electrode deployment system for pain management, knee and hip alloy implants, polymeric implants, RF cauterizing clamps, micro-electrodes, POC microfluidic hemo related devices (coagulation, cell count, molecular sensors), and some stem cell and embryo research.

Hao founded Biocrede Inc. in 2012, which received 3 NIH SBIR/STTR Phase I awards in 2014, and focuses on medical technologies such as catheters that prevent catheter associated urinary tract infections and tunneled dialysis catheter dysfunction, stem cell technologies, and others. He previously helped spin-off more than 40 patents from Honeywell to form Ativa Med, setup a medical device stent manufacturing site, and acted as director of sales for a high-end medical and pharmaceutical raman quality systems in Latin America.

For the past six years, Hao has worked with researchers at the University of Michigan to develop translational research opportunities. He has in depth knowledge in the design of nephrostomy balloon catheters for Gyrus ACMI (Olympus) to compete against Bard, Boston Scientific, and Cook’s nephrostomy balloon catheters. Hao has managed bio/medical technology development projects for Ethicon Endo Surgery, Dupont, Covidien, Biomet, Medtronic, Abbott, Boston Scientific, Synthes and others via Accellent.